Statement Of Cash Flows [Abstract]

Hyloris Pharmaceuticals SA - Filing #5880972

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
788,000 EUR
613,000 EUR
Adjustments for decrease (increase) in trade and other receivables
1,881,000 EUR
29,000 EUR
Adjustments for increase (decrease) in trade and other payables
140,000 EUR
1,050,000 EUR
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
648,000 EUR
349,000 EUR
Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates
81,000 EUR
147,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.